The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Mycoplasma Hyopneumoniae Vaccine Market Research Report 2024
Synopsis
Mycoplasma Hyopneumoniae Vaccine can effectively prevent Mycoplasma suis. Mycoplasma pneumonia has always been regarded as one of the most widespread diseases that cause major economic losses to the pig industry.
The global Mycoplasma Hyopneumoniae Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Mycoplasma Hyopneumoniae Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mycoplasma Hyopneumoniae Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Mycoplasma Hyopneumoniae Vaccine include Zoetis, Merck, Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health, Qilu Animal Health, Ruipu, Shanghai Hile Bio-Technology Co., Ltd. and CAHIC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mycoplasma Hyopneumoniae Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mycoplasma Hyopneumoniae Vaccine.
Report Scope
The Mycoplasma Hyopneumoniae Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mycoplasma Hyopneumoniae Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mycoplasma Hyopneumoniae Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Merck
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Qilu Animal Health
Ruipu
Shanghai Hile Bio-Technology Co., Ltd.
CAHIC
Pulike
Harbin Pharmaceutical Group
Segment by Type
Live
Inactivated
Segment by Application
Piglets
Adult Pigs
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Mycoplasma Hyopneumoniae Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Mycoplasma Hyopneumoniae Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Mycoplasma Hyopneumoniae Vaccine can effectively prevent Mycoplasma suis. Mycoplasma pneumonia has always been regarded as one of the most widespread diseases that cause major economic losses to the pig industry.
The global Mycoplasma Hyopneumoniae Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Mycoplasma Hyopneumoniae Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Mycoplasma Hyopneumoniae Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Mycoplasma Hyopneumoniae Vaccine include Zoetis, Merck, Boehringer Ingelheim, Ceva Santé Animale, Elanco Animal Health, Qilu Animal Health, Ruipu, Shanghai Hile Bio-Technology Co., Ltd. and CAHIC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Mycoplasma Hyopneumoniae Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mycoplasma Hyopneumoniae Vaccine.
Report Scope
The Mycoplasma Hyopneumoniae Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Mycoplasma Hyopneumoniae Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mycoplasma Hyopneumoniae Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Merck
Boehringer Ingelheim
Ceva Santé Animale
Elanco Animal Health
Qilu Animal Health
Ruipu
Shanghai Hile Bio-Technology Co., Ltd.
CAHIC
Pulike
Harbin Pharmaceutical Group
Segment by Type
Live
Inactivated
Segment by Application
Piglets
Adult Pigs
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Mycoplasma Hyopneumoniae Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Mycoplasma Hyopneumoniae Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Mycoplasma Hyopneumoniae Vaccine Market Overview
1.1 Product Overview and Scope of Mycoplasma Hyopneumoniae Vaccine
1.2 Mycoplasma Hyopneumoniae Vaccine Segment by Type
1.2.1 Global Mycoplasma Hyopneumoniae Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Live
1.2.3 Inactivated
1.3 Mycoplasma Hyopneumoniae Vaccine Segment by Application
1.3.1 Global Mycoplasma Hyopneumoniae Vaccine Market Value by Application: (2024-2030)
1.3.2 Piglets
1.3.3 Adult Pigs
1.4 Global Mycoplasma Hyopneumoniae Vaccine Market Size Estimates and Forecasts
1.4.1 Global Mycoplasma Hyopneumoniae Vaccine Revenue 2019-2030
1.4.2 Global Mycoplasma Hyopneumoniae Vaccine Sales 2019-2030
1.4.3 Global Mycoplasma Hyopneumoniae Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Mycoplasma Hyopneumoniae Vaccine Market Competition by Manufacturers
2.1 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Mycoplasma Hyopneumoniae Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Mycoplasma Hyopneumoniae Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Mycoplasma Hyopneumoniae Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Mycoplasma Hyopneumoniae Vaccine, Product Type & Application
2.7 Mycoplasma Hyopneumoniae Vaccine Market Competitive Situation and Trends
2.7.1 Mycoplasma Hyopneumoniae Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Mycoplasma Hyopneumoniae Vaccine Players Market Share by Revenue
2.7.3 Global Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Mycoplasma Hyopneumoniae Vaccine Retrospective Market Scenario by Region
3.1 Global Mycoplasma Hyopneumoniae Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Mycoplasma Hyopneumoniae Vaccine Global Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2019-2030
3.2.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2019-2024
3.2.2 Global Mycoplasma Hyopneumoniae Vaccine Sales by Region: 2025-2030
3.3 Global Mycoplasma Hyopneumoniae Vaccine Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2019-2030
3.3.1 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2019-2024
3.3.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2025-2030
3.4 North America Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
3.4.1 North America Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2030)
3.4.3 North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
3.5.1 Europe Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2030)
3.5.3 Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
3.7.1 Latin America Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Type (2019-2030)
4.1.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Type (2019-2024)
4.1.2 Global Mycoplasma Hyopneumoniae Vaccine Sales by Type (2025-2030)
4.1.3 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2019-2030)
4.2.1 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2019-2024)
4.2.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2025-2030)
4.2.3 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Application (2019-2030)
5.1.1 Global Mycoplasma Hyopneumoniae Vaccine Sales by Application (2019-2024)
5.1.2 Global Mycoplasma Hyopneumoniae Vaccine Sales by Application (2025-2030)
5.1.3 Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2019-2030)
5.2.1 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2019-2024)
5.2.2 Global Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2025-2030)
5.2.3 Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Mycoplasma Hyopneumoniae Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Corporation Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Zoetis Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Ceva Santé Animale
6.4.1 Ceva Santé Animale Corporation Information
6.4.2 Ceva Santé Animale Description and Business Overview
6.4.3 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.4.5 Ceva Santé Animale Recent Developments/Updates
6.5 Elanco Animal Health
6.5.1 Elanco Animal Health Corporation Information
6.5.2 Elanco Animal Health Description and Business Overview
6.5.3 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.5.5 Elanco Animal Health Recent Developments/Updates
6.6 Qilu Animal Health
6.6.1 Qilu Animal Health Corporation Information
6.6.2 Qilu Animal Health Description and Business Overview
6.6.3 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.6.5 Qilu Animal Health Recent Developments/Updates
6.7 Ruipu
6.6.1 Ruipu Corporation Information
6.6.2 Ruipu Description and Business Overview
6.6.3 Ruipu Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ruipu Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.7.5 Ruipu Recent Developments/Updates
6.8 Shanghai Hile Bio-Technology Co., Ltd.
6.8.1 Shanghai Hile Bio-Technology Co., Ltd. Corporation Information
6.8.2 Shanghai Hile Bio-Technology Co., Ltd. Description and Business Overview
6.8.3 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.8.5 Shanghai Hile Bio-Technology Co., Ltd. Recent Developments/Updates
6.9 CAHIC
6.9.1 CAHIC Corporation Information
6.9.2 CAHIC Description and Business Overview
6.9.3 CAHIC Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CAHIC Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.9.5 CAHIC Recent Developments/Updates
6.10 Pulike
6.10.1 Pulike Corporation Information
6.10.2 Pulike Description and Business Overview
6.10.3 Pulike Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pulike Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.10.5 Pulike Recent Developments/Updates
6.11 Harbin Pharmaceutical Group
6.11.1 Harbin Pharmaceutical Group Corporation Information
6.11.2 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Description and Business Overview
6.11.3 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product Portfolio
6.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Mycoplasma Hyopneumoniae Vaccine Industry Chain Analysis
7.2 Mycoplasma Hyopneumoniae Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Mycoplasma Hyopneumoniae Vaccine Production Mode & Process
7.4 Mycoplasma Hyopneumoniae Vaccine Sales and Marketing
7.4.1 Mycoplasma Hyopneumoniae Vaccine Sales Channels
7.4.2 Mycoplasma Hyopneumoniae Vaccine Distributors
7.5 Mycoplasma Hyopneumoniae Vaccine Customers
8 Mycoplasma Hyopneumoniae Vaccine Market Dynamics
8.1 Mycoplasma Hyopneumoniae Vaccine Industry Trends
8.2 Mycoplasma Hyopneumoniae Vaccine Market Drivers
8.3 Mycoplasma Hyopneumoniae Vaccine Market Challenges
8.4 Mycoplasma Hyopneumoniae Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Mycoplasma Hyopneumoniae Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Mycoplasma Hyopneumoniae Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Mycoplasma Hyopneumoniae Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Mycoplasma Hyopneumoniae Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Mycoplasma Hyopneumoniae Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Mycoplasma Hyopneumoniae Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Mycoplasma Hyopneumoniae Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Mycoplasma Hyopneumoniae Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Mycoplasma Hyopneumoniae Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mycoplasma Hyopneumoniae Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Mycoplasma Hyopneumoniae Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Mycoplasma Hyopneumoniae Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Mycoplasma Hyopneumoniae Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Mycoplasma Hyopneumoniae Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Mycoplasma Hyopneumoniae Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Mycoplasma Hyopneumoniae Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Mycoplasma Hyopneumoniae Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. Zoetis Corporation Information
Table 71. Zoetis Description and Business Overview
Table 72. Zoetis Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Zoetis Mycoplasma Hyopneumoniae Vaccine Product
Table 74. Zoetis Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Merck Mycoplasma Hyopneumoniae Vaccine Product
Table 79. Merck Recent Developments/Updates
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Boehringer Ingelheim Mycoplasma Hyopneumoniae Vaccine Product
Table 84. Boehringer Ingelheim Recent Developments/Updates
Table 85. Ceva Santé Animale Corporation Information
Table 86. Ceva Santé Animale Description and Business Overview
Table 87. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Ceva Santé Animale Mycoplasma Hyopneumoniae Vaccine Product
Table 89. Ceva Santé Animale Recent Developments/Updates
Table 90. Elanco Animal Health Corporation Information
Table 91. Elanco Animal Health Description and Business Overview
Table 92. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Elanco Animal Health Mycoplasma Hyopneumoniae Vaccine Product
Table 94. Elanco Animal Health Recent Developments/Updates
Table 95. Qilu Animal Health Corporation Information
Table 96. Qilu Animal Health Description and Business Overview
Table 97. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Qilu Animal Health Mycoplasma Hyopneumoniae Vaccine Product
Table 99. Qilu Animal Health Recent Developments/Updates
Table 100. Ruipu Corporation Information
Table 101. Ruipu Description and Business Overview
Table 102. Ruipu Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Ruipu Mycoplasma Hyopneumoniae Vaccine Product
Table 104. Ruipu Recent Developments/Updates
Table 105. Shanghai Hile Bio-Technology Co., Ltd. Corporation Information
Table 106. Shanghai Hile Bio-Technology Co., Ltd. Description and Business Overview
Table 107. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Shanghai Hile Bio-Technology Co., Ltd. Mycoplasma Hyopneumoniae Vaccine Product
Table 109. Shanghai Hile Bio-Technology Co., Ltd. Recent Developments/Updates
Table 110. CAHIC Corporation Information
Table 111. CAHIC Description and Business Overview
Table 112. CAHIC Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. CAHIC Mycoplasma Hyopneumoniae Vaccine Product
Table 114. CAHIC Recent Developments/Updates
Table 115. Pulike Corporation Information
Table 116. Pulike Description and Business Overview
Table 117. Pulike Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Pulike Mycoplasma Hyopneumoniae Vaccine Product
Table 119. Pulike Recent Developments/Updates
Table 120. Harbin Pharmaceutical Group Corporation Information
Table 121. Harbin Pharmaceutical Group Description and Business Overview
Table 122. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Harbin Pharmaceutical Group Mycoplasma Hyopneumoniae Vaccine Product
Table 124. Harbin Pharmaceutical Group Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Mycoplasma Hyopneumoniae Vaccine Distributors List
Table 128. Mycoplasma Hyopneumoniae Vaccine Customers List
Table 129. Mycoplasma Hyopneumoniae Vaccine Market Trends
Table 130. Mycoplasma Hyopneumoniae Vaccine Market Drivers
Table 131. Mycoplasma Hyopneumoniae Vaccine Market Challenges
Table 132. Mycoplasma Hyopneumoniae Vaccine Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Mycoplasma Hyopneumoniae Vaccine
Figure 2. Global Mycoplasma Hyopneumoniae Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Type in 2023 & 2030
Figure 4. Live Product Picture
Figure 5. Inactivated Product Picture
Figure 6. Global Mycoplasma Hyopneumoniae Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Mycoplasma Hyopneumoniae Vaccine Market Share by Application in 2023 & 2030
Figure 8. Piglets
Figure 9. Adult Pigs
Figure 10. Global Mycoplasma Hyopneumoniae Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Mycoplasma Hyopneumoniae Vaccine Market Size (2019-2030) & (US$ Million)
Figure 12. Global Mycoplasma Hyopneumoniae Vaccine Sales (2019-2030) & (K Units)
Figure 13. Global Mycoplasma Hyopneumoniae Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 14. Mycoplasma Hyopneumoniae Vaccine Report Years Considered
Figure 15. Mycoplasma Hyopneumoniae Vaccine Sales Share by Manufacturers in 2023
Figure 16. Global Mycoplasma Hyopneumoniae Vaccine Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Mycoplasma Hyopneumoniae Vaccine Players: Market Share by Revenue in 2023
Figure 18. Mycoplasma Hyopneumoniae Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Mycoplasma Hyopneumoniae Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2019-2030)
Figure 21. North America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2019-2030)
Figure 22. United States Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2019-2030)
Figure 25. Europe Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2019-2030)
Figure 26. Germany Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2019-2030)
Figure 33. China Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2019-2030)
Figure 43. Latin America Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Mycoplasma Hyopneumoniae Vaccine by Type (2019-2030)
Figure 53. Global Revenue Market Share of Mycoplasma Hyopneumoniae Vaccine by Type (2019-2030)
Figure 54. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Mycoplasma Hyopneumoniae Vaccine by Application (2019-2030)
Figure 56. Global Revenue Market Share of Mycoplasma Hyopneumoniae Vaccine by Application (2019-2030)
Figure 57. Global Mycoplasma Hyopneumoniae Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 58. Mycoplasma Hyopneumoniae Vaccine Value Chain
Figure 59. Mycoplasma Hyopneumoniae Vaccine Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
